The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon
Abstract
BACKGROUND: Immunotherapy for advanced melanoma induces serologic and clinical manifestations of autoimmunity. We assessed the prognostic significance of autoimmunity in patients with stage IIB, IIC, or III melanoma who were treated with high-dose adjuvant interferon alfa-2b. METHODS: We enrolled 200 patients in a substudy of a larger, ongoing randomized trial. Blood was obtained before the initiation of intravenous interferon therapy, after 1 month of therapy, and at 3, 6, 9, and 12 months. Serum was tested for antithyroid, antinuclear, anti-DNA, and anticardiolipin autoantibodies, and patients were examined for vitiligo. RESULTS: The median duration of follow-up was 45.6 months. Relapse occurred in 115 patients, and 82 patients died. The median relapse-free survival was 28.0 months, and the median overall survival was 58.7 months. Autoantibodies and clinical manifestations of autoimmunity were detected in 52 patients (26 percent). The median relapse-free survival was 16.0 months among patients without autoimmunity (108 of 148 had a relapse) and was not reached among patients with autoimmunity (7 of 52 had a relapse). The median survival was 37.6 months among patients without autoimmunity (80 of 148 died) and was not reached among patients with autoimmunity (2 of 52 died). In univariate and multivariate regression analyses, autoimmunity was an independent prognostic marker for improved relapse-free survival and overall survival (P<0.001). CONCLUSIONS: The appearance of autoantibodies or clinical manifestations of autoimmunity during treatment with interferon alfa-2b is associated with statistically significant improvements in relapse-free survival and overall survival in patients with melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Balch, C. M., Soong, S.-J., Gershenwald, J. E., Thompson, J. F., Reintgen, D. S., Cascinelli, N., Urist, M., McMasters, K. M., Ross, M. I., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3622 · Cited by 2,388
Self-citationKirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.7 · Cited by 2,094
Self-citationPhan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Kirkwood, J. M., Ibrahim, J. G., Sondak, V. K., Richards, J., Flaherty, L. E., Ernstoff, M. S., Smith, T. J., Rao, U., Steele, M., & Blum, R. H. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2444 · Cited by 912
Self-citationKirkwood, J. M., Ibrahim, J. G., Sosman, J. A., Sondak, V. K., Agarwala, S. S., Ernstoff, M. S., & Rao, U. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2370 · Cited by 898
Self-citationKirkwood, J. M., Manola, J., Ibrahim, J., Sondak, V., Ernstoff, M. S., & Rao, U. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1103-3 · Cited by 552
Self-citationSide effects of high-dose interferon therapy for chronic hepatitis C
Okanoue, T., Sakamoto, S., Itoh, Y., Minami, M., Yasui, K., Sakamoto, M., Nishioji, K., Katagishi, T., Nakagawa, Y., Tada, H., et al. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80113-9 · Cited by 460
Sanderson, K., Scotland, R., Lee, P., Liu, D., Groshen, S., Snively, J., Sian, S., Nichol, G., Davis, T., Keler, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.128 · Cited by 434
Vitiligo in Patients with Melanoma: Normal Tissue Antigens Can Be Targets for Cancer Immunotherapy
Rosenberg, S. A., & White, D. E. (1996) · Journal of Immunotherapy · doi:10.1097/00002371-199601000-00009 · Cited by 333
Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells
Atkins, M. B., Mier, J. W., Parkinson, D. R., Gould, J. A., Berkman, E. M., & Kaplan, M. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806163182401 · Cited by 318
Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma
Phan, G. Q., Attia, P., Steinberg, S. M., White, D. E., & Rosenberg, S. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3477 · Cited by 302
Vitiligo in patients with metastatic melanoma: A good prognostic sign
Nordlund, J. J., Kirkwood, J. M., Forget, B. M., Milton, G., Albert, D. M., & Lerner, A. B. (1983) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(83)70182-9 · Cited by 288
Self-citationMechanisms and Management of Toxicities Associated With High-Dose Interferon Alfa-2b Therapy
Kirkwood, J. M., Bender, C., Agarwala, S., Tarhini, A., Shipe-Spotloe, J., Smelko, B., Donnelly, S., & Stover, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.052 · Cited by 200
Self-citationKOH, L. K. H., GREENSPAN, F. S., & YEO, P. P. B. (1997) · Thyroid · doi:10.1089/thy.1997.7.891 · Cited by 185
Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy
Deutsch, M., Dourakis, S., Manesis, E. K., Gioustozi, A., Hess, G., Horsch, A., & Hadziyannis, S. (1997) · Hepatology · doi:10.1002/hep.510260127 · Cited by 182
Prognostic significance of hypopigmentation in malignant melanoma
Bystryn, J. ‐. (1987) · Archives of Dermatology · doi:10.1001/archderm.123.8.1053 · Cited by 176
Kälkner, K. M. (1998) · QJM · doi:10.1093/qjmed/91.6.393 · Cited by 104
Weijl, N. I., Harst, D. V. D., Brand, A., Kooy, Y. M. C., Luxemburg, S. V., Schroder, J., Lentjes, E. G. W. M., ROOD, J. J. V., Cleton, F. J., & Osanto, S. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1376 · Cited by 99
Krouse, R. S., Royal, R. E., Heywood, G., Weintraub, B. D., White, D. E., Steinberg, S. M., Rosenberg, S. A., & Schwartzentruber, D. J. (1995) · Journal of Immunotherapy · doi:10.1097/00002371-199511000-00008 · Cited by 94
Vitiligo and Cutaneous Melanoma
Schallreuter, K. U., Levenig, C., & Berger, J. (2009) · Dermatologica · doi:10.1159/000247693 · Cited by 92
Franzke, A., Peest, D., Probst‐Kepper, M., Buer, J., Kirchner, G. I., Brabant, G. E., Kirchner, H. H., Ganser, A., & Atzpodien, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.529 · Cited by 87
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma
Becker, J. C., Winkler, B., Klingert, S., & Bröcker, E. (1994) · Cancer · doi:10.1002/1097-0142(19940315)73:6<1621::aid-cncr2820730613>3.0.co;2-e · Cited by 77
Wesche, B., Jaeckel, E., Trautwein, C., Wedemeyer, H., Falorni, A., Frank, H., Mühlen, A. V. Z., Manns, M.-P., & Brabant, G. E. (2001) · Gut · doi:10.1136/gut.48.3.378 · Cited by 69
Scalzo, S., Gengaro, A., Boccoli, G., Masciulli, R., Giannella, G., Salvo, G., Marolla, P., Carlini, P., Massimini, G., Holdener, E. E., et al. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90275-x · Cited by 61
CTLA-4 Blockade: Unveiling Immune Regulation
Dranoff, G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.923 · Cited by 46
Autoimmune Thyroid Dysfunctions in Hematologic Malignancies Treated with Alpha-lnterferon
Vallisa, D., Cavanna, L., Bertè, R., Merli, F., Ghisoni, F., & Buscarini, L. (2009) · Acta Haematologica · doi:10.1159/000204086 · Cited by 26
Tumor size, age and stage in patient detected breast cancer
Kaplan, H. G., Malmgren, J., & Atwood, M. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.716 · Cited by 8
Cited by
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1136 · Cited by 863
Cytokines in Cancer Immunotherapy
Lee, S., & Margolin, K. (2011) · Cancers · doi:10.3390/cancers3043856 · Cited by 693
Metadata
- Authors
- Gogas, H., Ioannovich, J., Dafni, U., Stavropoulou-Giokas, C., Frangia, K., Tsoutsos, D., Panagiotou, P., Polyzos, A., Papadopoulos, O., Stratigos, A., Markopoulos, C., Bafaloukos, D., Pectasides, D., Fountzilas, G., & Kirkwood, J. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-02-16
- Volume
- 354
- Issue
- 7
- Pages
- 709-718
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4256189622
- Cited by
- 566
- References
- 29
- FWCI
- 28.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.